Furthermore, a recent study showed that a test for the quantification of hs-cTnT (Roche Elecsys) showed significant higher values for TnT in patients with skeletal muscle disorders (SMDs) versus control subjects without SMDs (median: 16 ng/L with an interquartile range (IQR) of 7–32.5 ng/L versus 5 ng/L (an IQR of 3–9 ng/L; p < 0.001)), whereas the complementary assay for hs-cTnI did not show significant higher values. The gene discussed is TNNI3; the disease is skeletal muscle disorder.